Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT02898181

Low Level Tragus Stimulation in Acute Decompensated Heart Failure

Led by University of Oklahoma · Updated on 2025-05-28

100

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Acute Decompensated Heart Failure (ADHF) is a major cause of morbidity and mortality. It is associated with increased systemic inflammation. Previous studies have demonstrated increased levels of cytokines such as C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10) and Tumor Necrosis Factor alpha (TNFα) in patients with heart failure (HF). Increased activity of sympathetic nervous system in ADHF is linked to inflammation. Previous anti-inflammatory drug therapies in HF have demonstrated no significant impact on cardiovascular outcomes. Low-level vagus nerve stimulation (LLVNS) is a non-invasive way to modulate autonomic tone and thereby inflammation. Vagal nerve stimulation is thought to increase the parasympathetic activity and suppress the sympathetic activity. Clinical studies of vagal stimulation in chronic HF have been negative. Recent experimental and clinical data suggest that low level tragus nerve stimulation (LLTNS) may produce the same desired neuromodulator effect compared to LLVNS. It is however unknown if LLTNS in ADHF will directly lead to a reduction in the levels of pro-inflammatory cytokines (CRP, IL-1, IL-6 and TNF-α) and an increase in the level of anti-inflammatory marker IL-10. heart rate variability may also be abnormal in ADHF. The objective of this proposal is to determine the impact of LLTS on inflammatory cytokines, heart failure biomarkers(Pro BNP) and HRV in patients with ADHF.In addition we will study the impact on dyspnea resolution and change in renal function during hospitalization. Patients will be randomized to either active or sham stimulation (2 hours daily). Serum collected will (post-admission and discharge day) will be used for cytokine measurement. We will also measure daily ECG to assess HRV and patient assessed dyspnea scale.This investigation will likely establish the first evidence of the effects of LLTS on the suppression of inflammation and improvement in dyspnea, natriuretic peptides, renal function and HRV in patients presenting with ADHF.

CONDITIONS

Official Title

Low Level Tragus Stimulation in Acute Decompensated Heart Failure

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients admitted with Acute Decompensated Heart Failure (ADHF) aged 18 to 80 years
Not Eligible

You will not qualify if you...

  • Refusal to consent
  • Complex congenital heart disease such as Tetralogy of Fallot or single ventricle physiology
  • Recurrent vaso-vagal syncopal episodes
  • Unilateral or bilateral vagotomy
  • Sick sinus syndrome
  • Second or third degree AV block
  • Bifascicular block or prolonged first degree AV block (PR > 300 ms)
  • Pregnant patients
  • Prisoners
  • Advanced renal dysfunction (eGFR < 30, stage 4 or 5 chronic kidney disease)
  • Hepatitis C or HIV infection
  • Acute Myocardial infarction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

OUHSC

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

Loading map...

Research Team

T

Tarun Dasari, MD,MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here